Enhancing Extinction Learning in Post Traumatic Stress Disorder (PTSD)
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
Posttraumatic stress disorder (PTSD) is a condition that involves intense memories of a
traumatic event and intense, persistent feelings of anxiety. There are several effective
therapies for PTSD, but they are often time consuming. The investigators want to see if the
investigators can shorten treatment time while keeping therapy effective by adding a
medication called methylene blue, USP, taken orally as a pill, to the therapy. The specific
aims are: 1) To see whether medication plus psychotherapy improves PTSD symptoms more than
placebo plus psychotherapy or a waitlist; 2) To examine the long-term outcome of those
receiving medication plus psychotherapy 1 and 3 months after treatment has ended; 3) To
examine whether medication plus psychotherapy helps with depression, trauma-related
cognitions, and functioning.
Phase:
Phase 2
Details
Lead Sponsor:
University of Washington
Collaborators:
National Institute of Mental Health (NIMH) University of Pennsylvania University of Texas